nature neurOSCIenCe a r t I C l e S Schwann cells of the peripheral nervous system (PNS) ensheath and wrap myelin membranes around axons to maximize the efficiency of rapid saltatory conduction of action potentials. Functional defects of SCs contribute to various forms of peripheral neuropathies 1-3 . A recently defined autosomal dominant disorder, Mowat-Wilson syndrome (MOWS), is caused by mutations in ZEB2 (also called SIP1 or ZFHX1B), the gene that encodes zinc finger E-box-binding homeobox 2 protein. MOWS is characterized by a wide spectrum of congenital anomalies encompassing growth defects, intellectual disability, delayed motor development and neurocristopathies with defects in neural crest derivatives 4-6 . In mice, Zeb2 is critical for neurogenesis and gliogenesis in the CNS 7-9 . Recent studies indicate that Zeb2 can interact with NuRD, suggesting that NuRD association may be important to Zeb2 functions 4,10 . At present, whether and how Zeb2 controls SC differentiation and myelination remain elusive. Elucidation of Zeb2 functions in peripheral nerve cell development in addition to CNS neurogenesis may provide a better understanding of the etiology of neurological diseases associated with MOWS caused by ZEB2 mutations.
a r t I C l e S Schwann cells of the peripheral nervous system (PNS) ensheath and wrap myelin membranes around axons to maximize the efficiency of rapid saltatory conduction of action potentials. Functional defects of SCs contribute to various forms of peripheral neuropathies [1] [2] [3] . A recently defined autosomal dominant disorder, Mowat-Wilson syndrome (MOWS), is caused by mutations in ZEB2 (also called SIP1 or ZFHX1B), the gene that encodes zinc finger E-box-binding homeobox 2 protein. MOWS is characterized by a wide spectrum of congenital anomalies encompassing growth defects, intellectual disability, delayed motor development and neurocristopathies with defects in neural crest derivatives [4] [5] [6] . In mice, Zeb2 is critical for neurogenesis and gliogenesis in the CNS [7] [8] [9] . Recent studies indicate that Zeb2 can interact with NuRD, suggesting that NuRD association may be important to Zeb2 functions 4, 10 . At present, whether and how Zeb2 controls SC differentiation and myelination remain elusive. Elucidation of Zeb2 functions in peripheral nerve cell development in addition to CNS neurogenesis may provide a better understanding of the etiology of neurological diseases associated with MOWS caused by ZEB2 mutations.
Development and myelination of neural-crest-derived SCs are coordinately regulated by a spectrum of extracellular signals and intrinsic regulators. These comprise positive cues including neuregulin 1 (NRG1) 11, 12 and laminin-integrin signaling 13, 14 , G-protein-coupled receptors (GPCRs) such as Gpr126 (ref. 15 ) and negative cues including Notch signaling and Sox2 (ref. 16 ). Timely initiation of SC myelination not only demands a strict interplay between extrinsic cues and intracellular inputs, but also requires the precise balance of the activity of an intricate network of transcriptional regulators. Transcription factors such as the high mobility group (HMG)-type protein Sox10, the Pit-Oct-Unc (POU)homeodomain proteins Oct6 (also called Pou3f1) and Pou3f2 (also called Brn2), and the zinc-finger proteins Krox20 (also called Egr2) and YY1 are crucial for promoting SC myelination [17] [18] [19] [20] . How these multiple signaling pathways converge and coordinate the myelination program and, more importantly, what orchestrates the fine-tuning of proper transcriptional outputs are not fully understood.
Here, using SC-lineage-specific in vivo mutagenesis, we identified Zeb2 as a critical intrinsic timer controlling the onset of SC differentiation during normal myelination and also in remyelination after peripheral nerve injury. The predominant effects of Zeb2 during SC development are to directly repress a network of inhibitory pathways including Sox2 and Notch-Hey2 signaling. We further find that a single amino acid variant in ZEB2 seen in a patient with MOWS disrupts interaction with the HDAC1/2-NuRD co-repressor complex and abolishes the ability of ZEB2 to effect SC differentiation. Our data thus establish a critical role for HDAC1/2-NuRD-dependent Zeb2 activity in initiating SC differentiation and myelination through opposing Notch-and Sox2-mediated negative regulatory circuitry.
RESULTS

Dynamic Zeb2 expression during SC lineage development
To examine Zeb2 expression in SCs, we coimmunolabeled for Zeb2 and for SC lineage marker Sox10 in developing sciatic nerves (Fig. 1a) . The vast majority of Zeb2-positive cells were also Sox10-positive at postnatal day (P) 7. In keeping with its function as transcription regulator, Zeb2 was detected in the nuclei of Sox10 + SCs. Concurrent with the onset of myelination in the developing nerves, Zeb2 was highly expressed in SCs during the first 2 postnatal weeks, and the signal gradually declined as the animal reaches adulthood at 10 weeks (Fig. 1a) .
To further define Zeb2 levels during SC lineage progression, we examined Zeb2 mRNA expression using SC-enriched sciatic nerves at different stages by real-time quantitative PCR (qPCR). Consistently, Zeb2 transcripts were detected at the neonatal stage P0 and peaked at the perinatal stage P10, but then were reduced in adulthood ( Fig. 1b) .
Zeb2 mutant mice display severe motor deficits To determine the cell-autonomous function of Zeb2 in SC development, we generated conditional mutant mice lacking functional Zeb2 in SCs by breeding mice carrying a Zeb2 loxP-flanked allele (Zeb2 loxP/loxP ) 8, 21 with a SC-expressing Cre line driven by the Desert hedgehog (Dhh) promoter 17 (Fig. 1c) . We used Zeb2 loxP/+ ;Dhh-cre or Zeb2 loxP/loxP littermates as controls since they were phenotypically normal in SC development (Supplementary Fig. 1a-g) .
Cre-mediated inactivation of Zeb2 efficiently abrogated Zeb2 presence in Sox10 + SCs in peripheral nerves (Fig. 1d) . Zeb2 loxP/loxP ; Dhh-cre (hereafter referred to as Zeb2 cKO) mice were born in numbers predicted by Mendelian ratios. During the first postnatal week, mutant mice were essentially indistinguishable from littermate controls. Starting in the second week, however, all Zeb2 cKO mice began to develop severe tremor, unsteady gait and hindlimb paralysis, and the majority died by 8 weeks (Supplementary Fig. 2a) .
Upon tail suspension, mutant mice at P21 showed abnormal hindlimb clasping (Fig. 1e) . Zeb2 cKO sciatic nerves at P7 exhibited a thin and translucent appearance, in stark contrast to the thick, opaque nerves of control mice, suggesting a severe deficit at the onset of myelinogenesis (Fig. 1f) . Consistent with the overt clinical signs of hypomyelination in the Zeb2 cKO mutants, the motor unit function of mutant mice was severely impaired, as reflected by a marked reduction in conduction velocity (Fig. 1g ) measured by electrophysiological recordings of compound muscle action potentials (CMAPs) during electrical stimulation of the sciatic nerve in vivo. The nerve conduction velocity was reduced from 27.7 ± 2.7 m s −1 in littermate controls to 1.8 ± 0.1 m s −1 in the mutants at the young adult stage (P42), which is close to the level of the slower, thinly myelinated Aδ or unmyelinated C fiber conduction velocity in mice 22 (Fig. 1h) . Furthermore, the mean peak amplitudes and duration of CMAPs a r t I C l e S were also severely affected in Zeb2 cKO mice ( Fig. 1i,j) , accounting for the defect in motor function in Zeb2 mutants.
Zeb2-deficient SCs fail to myelinate in peripheral nerves
We evaluated myelinogenesis in Zeb2 cKO peripheral nerves by myelin basic protein (MBP) immunolabeling. In contrast to the robust expression in control nerves, MBP was scarcely expressed in the mutant sciatic nerves at P14 ( Fig. 2a) . Accordingly, expression of the major myelin genes Mbp and Mpz in sciatic nerves was virtually undetectable in mutants by in situ hybridization ( Fig. 2b) and qPCR ( Fig. 2c) . Ultrastructural examination by electron microscopy (EM) revealed that, whereas by P4 control SCs had established a 1:1 relationship with large-caliber axons and begun wrapping myelin membrane around axons, the majority of mutant SCs were associated with multiple axons and failed to initiate myelination, indicative of incomplete axonal sorting and a dysmyelination phenotype (Fig. 2d) . At P21, axon bundles ensheathed by Zeb2 cKO SCs remained essentially unsorted and unmyelinated ( Fig. 2e,f) , despite apparent normal SC process extension around associated axons ( Fig. 2f) . Moreover, small-diameter axons remained unsegregated in axon bundles with large diameter axons, further confirming sorting defects in Zeb2 cKO ( Supplementary Fig. 1c ). However, in testing for cutaneous thermal hypersensitivity, Zeb2 cKO showed a similar decrease in withdrawal latency to 50 °C water following tissue inflammation compared to their baseline responsiveness, as was seen with littermate controls (Supplementary Fig. 1h ).
Very few mutant mice survived to adulthood ( Supplementary  Fig. 2a ). The gross structure of peripheral nerves in rare Zeb2 cKO survivors at 2 months showed minifascicles of SCs and axons with no apparent sign of myelination, suggesting that Zeb2 loss in SCs leads to a sustained myelination block in peripheral nerves ( Fig. 2g) .
To bypass the possible influence of the Zeb2 loss during early SC development, we inactivated Zeb2 in the peripheral nerves of neonates using a tamoxifen-inducible Plp1-cre ERT driver 23 with tamoxifen administration from P0 to P4 (Fig. 2h) . By P14, more than half of the large axons were not properly sorted and remained unmyelinated in Zeb2 inducible knockout (iKO; Zeb2 loxP/loxP ;Plp1-cre ERT ) mutant nerves ( Fig. 2i,j) . The ultrastructural observations seen upon Zeb2 deletion in immature SCs suggest that Zeb2 is required for proper initiation of SC differentiation and myelination.
The diminished expression of Zeb2 in mature nerves ( Fig. 1a,b ) suggested a nonobligatory function in myelin maintenance. Accordingly, tamoxifen-induced deletion of Zeb2 in adult mice altered neither the myelin sheath's thickness nor its integrity in peripheral nerves ( Supplementary Fig. 2b ), suggesting a crucial role for Zeb2 in initiating or priming SC differentiation rather than maintaining myelin sheaths.
Zeb2 controls myelinogenic programs for SC differentiation
In Zeb2 cKO sciatic nerves at P7, we detected reduced levels of mRNAs encoding SC prodifferentiation regulators including Sox10, Krox20 and Oct6 (Fig. 3a) . In contrast, among known negative regulators, we a r t I C l e S observed an upregulation of Jag1, encoding a ligand for Notch, and Hes1 (Fig. 3b) . In step with their transcript levels, Oct6 and Krox20 proteins were essentially absent in mutant SCs in these Zeb2 cKO sciatic nerves ( Fig. 3c-e ). We further investigated Zeb2 functions in SC differentiation by Zeb2 siRNA knockdown in rat SC cultures, either in proliferation or differentiation medium. The expression of Oct6, Krox20 and major myelin genes, as well as their corresponding proteins, was markedly reduced in SCs that underwent Zeb2 knockdown ( Supplementary Fig. 3a-d Fig. 3e ).
The proportion of Sox10 + SCs among DAPI + cells in mutant nerves at P1 was comparable to that in control nerves ( Fig. 3d) , despite a slight reduction in SC number at P7 ( Fig. 3e) , which is likely due to the overall reduction in mature SCs. Accordingly, the SC proliferation rate revealed by proliferative marker Ki67 staining and 5-bromo-2′deoxyuridine (BrdU) incorporation appeared to increase substantially in Zeb2 mutant sciatic nerves ( Fig. 3f-h VOLUME 19 | NUMBER 8 | AUGUST 2016 nature neurOSCIenCe a r t I C l e S as determined by immunolabeling for cleaved caspase-3 in P1 sciatic nerves, was not significantly altered ( Fig. 3i,j) . This indicates that Zeb2 deletion arrests SCs at their immature stage by blocking the transition from immature SCs to Oct6 + Krox20 + differentiating SCs. Conversely, Zeb2 overexpression in SCs in vitro enhanced the induction of Oct6 and Krox20 (Fig. 3k ) and myelin gene expression ( Fig. 3l) . Notably, we detected a substantial downregulation of the Notch effector Rbpj upon enforced Zeb2 expression in SCs (Fig. 3m) . Thus, our data suggests that Zeb2 controls SC myelination by priming the transcriptional program that promotes SC differentiation, while attenuating the Rbpj-mediated Notch inhibitory pathway.
Zeb2 is required for SC differentiation during nerve repair Although Zeb2 was maintained at minimal levels in mature SCs, it was highly upregulated in SCs in regenerating sciatic nerves after injury ( Fig. 4a,b ). We hypothesized that Zeb2 is required for SC differentiation and ultimately remyelination during nerve repair. To test this, we employed the peripheral nerve transection model ( Fig. 4a) . After transection, SCs dedifferentiate, proliferate, establish a tissue bridge between the proximal and distal nerve stumps, and then guide regenerating axons across the bridge to reach the distal stump 25 , with subsequent SC differentiation and remyelination. To determine the role of Zeb2 in SC differentiation following nerve injury, we treated control (Zeb2 loxP/loxP or Zeb2 loxP/+ ; Plp1-cre ERT ) or Zeb2 loxP/loxP ;Plp1-cre ERT (Zeb2 iKO) mice at 4-6 weeks with tamoxifen before and after injury, which efficiently removed Zeb2 from transected nerves in the Zeb2 iKO mice ( Fig. 4c) . Sciatic nerves were removed for analysis 14 d after axotomy to assess SC differentiation, by which time a tissue bridge would have formed and axons guided by associated SCs as regeneration units would have proceeded to grow into the distal stump 25, 26 .
Here we focused our analysis on the regenerating site, defined as the SC-axon growth tip just proximal to the injury in the tissue bridge. In the regenerating region of Zeb2 iKO nerves, proliferation of mutant SCs (Ki67 + Sox10 + cells) was indistinguishable from that of control SCs, but the number of Sox10 + SCs was significantly reduced ( Fig. 4d-f ). Proliferating SCs were not observed in either control or mutant contralateral sciatic nerves (data not shown). In the regenerating nerve region, mutant SCs failed to differentiate properly, as revealed by a substantial decrease in Oct6 + or Krox20 + promyelinating SCs in mutant nerves ( Fig. 4g-i) .
We further assessed the extent of remyelination in control and Zeb2 iKO sciatic nerves by EM 8 weeks after surgery. During nerve regeneration, little, if any, radial sorting is required. In line with this, SCs lacking Zeb2 displayed normal association with axons in 1:1 ratios. While a majority of axons were remyelinated 8 weeks post injury in control nerves, Zeb2 iKO SCs were blocked at the promyelinating stage and failed to remyelinate ( Fig. 4j,k) . Myelin profiles in Zeb2 iKO nerves were scarce and axons that did show myelin profiles were primarily thinly myelinated. Together, our data suggest that Zeb2 is essential for SC myelination both in development and nerve regeneration.
Zeb2 represses SC differentiation inhibitor Sox2
Given severe SC myelination defects in both developing and regenerating nerves in Zeb2 mutants, we then sought to examine the expression of classic negative myelination regulators, such as Sox2 and c-Jun 27 . a r t I C l e S At perinatal stages, in keeping with the severe reduction of myelinating SCs marked by Krox20, expression of the immature SC marker Sox2, which maintains SCs in an undifferentiated state 27 , persisted even at P14, when Sox2 was rarely detectable in control nerves ( Fig. 5a,b) . Western blotting analysis corroborated Sox2 upregulation in postnatal mutant nerves ( Fig. 5c) . By contrast, c-Jun, another myelination inhibitor 28 , appeared normally expressed in mutant sciatic nerves compared with controls ( Fig. 5d,e ). Sox2 overexpression in SCs in vitro markedly suppressed expression of Krox20 upon induction of differentiation by dibutyryl cyclic AMP ( Fig. 5f,g) , though no apparent alterations of SC proliferation were detected ( Fig. 5h) . These observations suggest that upregulation of the differentiation inhibitor Sox2 caused by Zeb2 deletion inhibits SC differentiation.
Since Zeb2 can function as a transcriptional repressor 24 , we then hypothesized that it might directly target the promoter-proximal regulatory elements of Sox2 and inhibit its expression. We identified three conserved Zeb2 consensus binding sites in the promoter region of Sox2 within 5 kb upstream of the transcription start site (TSS) ( Fig. 5i) . Chromatin immunoprecipitation (ChIP) assays with a Zeb2-specific antibody showed a strong enrichment of endogenous Zeb2 binding to these sites in the Sox2 promoter region in differentiating SCs, but not to that of cells in their proliferating immature state ( Fig. 5i) . In contrast, no occupancy of Zeb2 to its candidate binding site in the Jun promoter was detected ( Supplementary Fig. 4a ). We also detected no enrichment of Zeb2 binding to Sox2 distal control regions (ChIP-PCR; Supplementary Fig. 4b ). Furthermore, Zeb2 overexpression in SCs significantly reduced Sox2 (Fig. 5j) . In accord, luciferase reporter assays showed that enforced Zeb2 expression in SCs effectively repressed Sox2 promoter activity ( Fig. 5k) . To address the specificity of Zeb2 action, we cotransfected the Zeb2 vector and a Sox2 promoter in which the Zeb2 binding site was mutated. Zeb2 repressive activity was significantly diminished, and luciferase reporter activity was restored to control levels ( Fig. 5k) . Together, our data indicate that Zeb2 directly targets the Sox2 promoter and inhibits Sox2 expression to promote terminal SC differentiation.
Zeb2 regulates multiple SC differentiation pathways
To identify potential additional Zeb2 targets that regulate SC differentiation, we performed RNA-seq of control and Zeb2 npg a r t I C l e S cKO sciatic nerves at P7. Gene ontology analysis of differentially regulated genes indicated that the functions of downregulated genes were particularly pertinent to lipid biosynthesis, myelination and SC differentiation ( Fig. 6a ), whereas those of upregulated genes could be classified into categories involving cell proliferation control, adhesion and extracellular matrix organization ( Fig. 6b) . Consistent with our in situ hybridization and qPCR results, we detected a strong downregulation of major myelin genes and differentiation regulatory genes such as Mbp, Mag, Mpz, Krox20 and Oct6, with a concomitant increase in genes encoding myelination inhibitors, including Sox2, Jag1 and Egr1 in Zeb2 cKO sciatic nerves ( Fig. 6c,d) . In keeping with the dramatic sorting defect in Zeb2 cKO nerves, we detected differential expression of selected genes involved in the regulation of radial sorting, including laminin α2 (Lama2), Cdc42 and integrin α6 (Itga6) (ref. 29 ; Supplementary  Fig. 5a,b) . The RNA-seq data demonstrated an upregulation of the transforming growth factor-β (TGFβ) signaling genes including Tgfb2, Bmper, Smad3 and Bmp7 in Zeb2 cKO sciatic nerves ( Fig. 6c) ; however, in contrast to the activation of bone morphogenetic protein (BMP)-receptor-activated Smads (Smad1, Smad5 and Smad8) and downregulation of Smad7 observed in oligodendrocytes lacking Zeb2 (ref. 8), we did not detect Smad activation or BMP signaling inhibition, assayed by phosphorylation of Smad1, Smad5 and Smad8 and gross Smad7 levels, respectively ( Supplementary Fig. 6 ).
These observations indicate that overall BMP-Smad signaling is not substantially altered in Zeb2 mutant SCs, suggesting that divergent mechanisms from those in CNS myelinogenesis 8 are at work by Zeb2 in SCs for the control of PNS myelination.
Zeb2 inhibits a Notch-Hey2 axis for SC differentiation We next set out to investigate other potential Zeb2-regulated signaling pathways for SC differentiation on the basis of transcriptome profiling analysis. We detected a cohort of signaling components in the Notch pathway that were significantly upregulated in Zeb2 cKO sciatic nerves ( Fig. 6c) . Among the upregulated genes, Hey2, a Hesrelated family basic helix-loop-helix effector of Notch 30 , displayed the most substantial increase in mRNA level compared to control nerves (Fig. 6d) . Because Hey2 functions as a transcriptional repressor in other systems, such as in cardiac and vascular development 30, 31 , we postulated that Hey2 might act as a blocker of SC differentiation. Hey2 transcript levels peaked at P5 and then rapidly declined to near zero at P15, which closely paralleled the expression profile of myelination inhibitors, such as Sox2 ( Fig. 6e) 27, 32 . We validated the increase in Hey2 mRNA and protein levels in Zeb2 cKO nerves by qPCR ( Fig. 6f ) and western blotting ( Fig. 6g) , respectively.
In seeking to determine whether Zeb2 could regulate Hey2 directly, we identified an evolutionarily conserved Zeb2 binding site upstream of the TSS and found that Zeb2 binding was enriched on the Hey2 promoter in differentiating SCs, but not in proliferating cells (Fig. 6h) . ChIP of the distal control region of Hey2 showed no Zeb2 binding ( Supplementary Fig. 4b ). Moreover, enforced Zeb2 expression in SCs significantly downregulated Hey2 (Fig. 6i) . Zeb2 overexpression in SCs repressed Hey2 promoter activity, and this repression was partially abolished when the Zeb2-binding site in this promoter was mutated ( Fig. 6j) . Overexpression of Hey2 inhibited Krox20 induction in SCs cultured under differentiation conditions ( Fig. 6k,l) . In contrast, the proliferative capacity of SCs npg a r t I C l e S assessed by Ki67 expression with constitutive Hey2 expression was significantly higher than that of control GFP-transfected SCs (Fig. 6m,n) . These observations suggest that Hey2 inhibits SC differentiation by arresting SCs in an undifferentiated state and driving their proliferation and that Zeb2 directly represses Hey2, thereby promoting SC myelination.
To further confirm that Zeb2 downregulates Hey2 or Sox2 transcription in order to promote SC differentiation, we performed sequential siRNA-mediated knockdown experiments, first by Zeb2 knockdown in SCs and then followed 24 h later by either knockdown of Sox2 or Hey2 using siRNA. Subsequent knockdown of Sox2 or Hey2 in Zeb2-deficient SCs partially restored myelinassociated gene expression ( Fig. 6o,p) , indicating that Zeb2 drives SC differentiation via repression of inhibitory factor genes such as Sox2 and Hey2.
As Notch signaling negatively controls SC myelination 16 , we explored the possibility that Zeb2 promotes SC differentiation and myelination by opposing a Notch-pathway-mediated differentiation block. To this end, we generated Zeb2 cKO mice carrying a Notchresponsive GFP reporter transgene (Supplementary Fig. 7a) 33 . There was a striking induction of Notch-dependent GFP expression in Zeb2 mutant nerves (Fig. 7a) . Furthermore, overexpression of Zeb2 significantly repressed the reporter activity of a TP1 (the Epstein Barr virus terminal protein 1) promoter carrying RBP-Jκ (recombination signal-binding protein 1 for Jκ) binding sites ( Fig. 7b) , which are highly specific to Notch signaling activation 34 , suggesting that Zeb2 inhibits Notch signaling in SCs.
Notch inhibition restores differentiation of Zeb2-mutant SCs
To test whether activation of Notch signaling is responsible for the differentiation failure in Zeb2-deficient SCs, we treated scrambled-siRNA and Zeb2-knockdown SCs over 4 d with the Notch inhibitor DAPT (5 µM), which inhibits γ-secretase, a protease required for Notch1 activation 35 . The addition of DAPT efficiently inhibited gene expression of Jag1 and Hey2 in scramble-transfected SCs (Fig. 7c) , whereas this treatment did not alter Zeb2 levels. In accord, SCs with Zeb2 knockdown showed increased levels of the Notch signaling genes Jag1 and Hey2. DAPT treatment effectively reduced expression of these genes (Fig. 7c ) and restored expression of major myelin genes (for example, Mpz, Cnp) to normal levels in Zeb2-knockdown SCs (Fig. 7d) . Notch inhibition by DAPT also partially rescued the otherwise perturbed induction of Oct6 in differentiating SCs with Zeb2 knockdown (Fig. 7d-f) . Strikingly, treatment of Notch inhibitor LY411575 in vivo led to a robust increase in Krox20 + SCs and appearance of MBP + or 
Hey2 (Fig. 7g,h) . Furthermore, blocking Notch signaling transduction by delivering a lentivirus expressing a dominant-negative form of the Notch coactivator Mastermind (DN-MAML) 36 reduced Hey2 or Jag1 expression and partially restored expression of Krox20 in Zeb2-knockdown SCs (Fig. 7i,j) . Collectively, our data suggest that Zeb2 inhibits Notch activation, at least in part, by suppressing its downstream effector Hey2, thereby promoting differentiation of SCs from their undifferentiated state.
Zeb2 recruits HDAC to antagonize differentiation inhibition
The observation that Zeb2 could effectively suppress multiple differentiation inhibitory pathways prompted us to postulate that Zeb2 functions by forming a co-repressor complex. A previous study of the functional domain of Zeb2 identified a NuRD-interacting motif (NIM) close to the N terminus of Zeb2, which is similar to the minimal domain needed for NuRD recruitment identified in the transcription factor Sall1 (refs. 10,37). Zeb2 associates with NuRD components that include histone deacetylases HDAC1 and HDAC2 (ref. 10 ). HDAC1 and HDAC2 control various stages of SC development; conditional inactivation of HDAC1 and HDAC2 in the SC lineage impairs radial sorting, SC development and myelination 38, 39 , a result that closely resembles the Zeb2 cKO phenotype. We therefore investigated the possibility that Zeb2 may interact with HDAC in the context of a NuRD co-repressor complex to suppress negative myelination regulators. Co-expression of Zeb2 together with HDAC1 or HDAC2 enhanced the repression of Hey2 and Sox2, to an extent much greater than that of Zeb2 overexpression alone, in SCs (Fig. 8a) .
By coimmunoprecipitation, we determined that HDAC1 and HDAC2 were present in a complex with Zeb2 ( Fig. 8b) .
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Zeb2 cKO; EGFP Notch EGFP Sox10 ; Fig. 8c ). Strikingly, we found that ZEB2 R22G was sufficient to abolish HDAC1 and HDAC2 recruitment to the ZEB2 complex (Fig. 8d) . Moreover, this missense mutation in ZEB2 markedly disrupted ZEB2 interaction with other NuRD subunits as determined by coimmunoprecipitation,
whereas CtBP (C-terminal-binding protein 1) binding was unaffected ( Fig. 8e and Supplementary Fig. 7b ). We further confirmed the endogenous interaction of Zeb2 with NuRD complex components, including HDAC1, HDAC2 and Mi2/Chd4, in rat SCs (Fig. 8f) . Most notably, exogenous expression of ZEB2 R22G markedly diminished the induction of Oct6 and Krox20 in SCs (Fig. 8g-i) . However, overexpressing a Zeb2 mutant protein with deletion of CtBP-interacting a r t I C l e S domains (Zeb2 ∆CID ) 40 did not alter induction of either Oct6 (Fig.  8g-h) or Krox20 (Fig. 8i) in SCs. Accordingly, enforced ZEB2 R22G expression in SCs also lost the capacity to repress Zeb2 target genes, such as Hey2, Sox2 and Jag1, or to activate the transcription of the myelin-related genes Oct6, Krox20 and Cnp (Fig. 8j-k) .
To determine whether recruitment of HDAC1 and HDAC2 by Zeb2 is required for target expression, we performed ChIP-qPCR in Zeb2-deficient SCs. The reduction of Zeb2 in SCs significantly compromised the enrichment of HDAC1 on the Zeb2-consensus binding regions in the promoters of Zeb2 target genes, such as Sox2, Oct6 and Hey2, in Zeb2-knockdown SCs (Fig. 8l) . In contrast, HDAC1 occupancy on the promoter of a non-Zeb2 target, Jun, in Zeb2-knockdown SCs was comparable with that in IgG controls (Fig. 8l) . Similar results were also obtained for HDAC2 recruitment (data not shown). This suggests that the Zeb2-HDAC1-HDAC2 complex is required for the regulation of target gene transcription in SCs. Thus, our findings indicate that Zeb2 represses SC differentiation inhibitors by associating with the HDAC1-HDAC2-NuRD co-repressor complex to promote SC myelination.
DISCUSSION
In this study, we provided in vivo genetic evidence for the critical function of Zeb2 in SC precursor differentiation and peripheral nerve myelination, as well as remyelination during nerve regeneration, consistent with the observations by Quintes et al. 41 in this issue. We establish Zeb2 as a key regulatory switch that controls the timing for the onset of normal SC differentiation and remyelination after injury. Furthermore, our findings reveal that Zeb2 cooperates with a HDAC1-HDAC2-NuRD chromatin-remodeling complex as a repressor targeting a network of inhibitory pathways, including Sox2 and Notch signaling, to drive SC differentiation, in conjunction with acting as a transcriptional activator of other target genes such as Oct6 (ref. 42 ). Moreover, we identified a Zeb2-modulated Notch-Hey2 signaling axis that blocks SC differentiation. Inhibition of Notch signaling partially rescues the SC differentiation defect caused by Zeb2 deficiency. Thus, Zeb2 regulates SC differentiation and myelination at least in part through de-repression of Notch signaling ( Supplementary  Fig. 7c,d) , pointing to the importance of HDAC1-HDAC2-NuRDdependent ZEB2 activity in MOWS-associated neuropathies.
Zeb2 recruits HDAC1/2-NuRD to control SC differentiation Delineation of differentially expressed genes by transcriptome analysis reveals that Zeb2 modulates inhibitory pathways, namely Sox2 effects and Notch-Hey2 signaling, during SC differentiation. Whether Zeb2 regulation of these individual inhibitory signals exists in parallel, and whether Zeb2 mediates its actions through other unidentified cofactors of these or other pathways to control SC myelination, would require further investigation. Nonetheless, we find that Zeb2 engages the HDAC1/2-NuRD complex to exert repressive activity on myelination inhibitory factors. Several studies have reported radial sorting and myelination impairment in mouse mutants with SC-specific inactivation of NuRD subunits or associated factors including Mi-2/Chd4 and HDAC1/2 38, 39, 43 as well as interacting partners such as NAB proteins 32, 44 . Co-expression of Zeb2, HDAC1 and HDAC2 in SCs further augments repression in expression of inhibitory genes Sox2 and Hey2. Remarkably, a single missense mutation, Zeb2 R22G , in the Zeb2 N-terminal NuRD-interacting domain completely abolishes its association with the HDAC1/2-NuRD and inhibits SC differentiation, likely due to inefficient repression of the aforementioned differentiation-inhibitory signals. Thus, by interacting with the HDAC1/2-NuRD complex 45 , Zeb2 may mediate its repressive activity to fine-tune transcription of the genes that negatively impact myelination. Taken together, our data indicate that Zeb2 acts as a key transcriptional repressor that effectively extinguishes multiple inhibitory pathways to direct the onset of SC differentiation and initiation of myelination.
A Notch-Hey2 axis for inhibiting SC differentiation Notch signaling regulates multiple stages of SC development, from promoting SC formation and proliferation to negatively regulating myelination 16 . Strikingly, in the absence of Zeb2, Notch signaling is turned on constitutively in sciatic nerves, exerting a negative regulatory effect on SC differentiation and myelination. We observed a substantial increase of proliferating immature SCs in Zeb2 mutants, which is consistent with the notion that activation of Notch signaling leads to increased SC proliferation 16 . The transcriptome profiling analysis further identified Hey2, a transcriptional repressor downstream of Notch 46 , as a Zeb2 target that suppresses Krox20 expression and blocks SC differentiation.
Nonetheless, unlike the sustained block of SC maturation in Zeb2 cKO nerves, genetically enforced Notch (i.e., NCID) expression in SCs does not completely prevent the initiation of myelinogenesis 16 . Therefore, we cannot rule out the possibility that Hey2 regulation of SC development may also be independent of canonical Notch signaling, as reported in other contexts 47, 48 . If such is the case, Zeb2regulated Hey2 would introduce an additional layer of repression to the already existing Notch inhibition on SC myelination.
Zeb2-deficient SCs exhibit persistent upregulation of Sox2 and a substantial increase in Sox2 + immature SCs in peripheral nerves. Sox2 has been shown to act downstream of Notch signaling in certain contexts. For instance, Notch activation induces Sox2 in sensory progenitors of the inner ear 49 . Elevation of Sox2 levels maintains SCs in the undifferentiated state by suppressing expression of SC differentiation markers such as Krox20 32 . Given that Hey2 overexpression inhibits Krox20 and increases the proliferation of immature SCs (Fig. 6k-n) , Notch-Hey2 activation may induce or maintain Sox2 expression to inhibit SC differentiation.
Distinct mechanisms of Zeb2 in CNS and PNS myelination
Recent studies of Zeb2 revealed that it activates Smad7 and inhibits the action of activated BMP-Smads on genes that would otherwise be inhibitory for oligodendrocyte myelinogenesis and hence promotes myelinogenesis in the CNS 8 . In contrast, the present study shows that Zeb2 does not appear to control SC differentiation via regulation of BMP-Smad signaling or Smad7 expression in the PNS, suggesting that Zeb2 controls SC myelination via a different mechanism. Here we find that Zeb2 directs SC differentiation by a disinhibition mechanism via antagonizing Notch-Hey2 signaling and Sox2 in the PNS, which was not observed in the CNS 8 . Furthermore, we found that in the PNS Zeb2, through recruitment of the HDAC1/2-NuRD, negatively regulates Sox2 and the Notch effector Hey2 to guard against the blockade of SC myelination mediated by these inhibitors.
In contrast to substantial downregulation of Sox10 in oligodendrocytes of the Zeb2 mutant spinal cord 8 , Zeb2 does not seem to regulate Sox10 (Fig. 3d,k) . However, we cannot exclude the possibility that Sox10 and Zeb2 coordinate to drive SC differentiation, similarly to the cooperative role they play in the enteric nervous system 50 . Alternatively, we observed a preferential recruitment of Zeb2 to the Oct6 promoter when SCs begin to differentiate (Supplementary Fig. 3e) . Given the downregulation of key promyelination regulators Oct6 and Krox20 in Zeb2-ablated sciatic nerves, our data suggests that Zeb2 may function as a dual-level switch npg a r t I C l e S control of SC differentiation through inactivating multiple differentiation inhibitors, including Notch signaling and Sox2, while promoting pro-myelinating factors Oct6 and Krox20 during SC development.
Zeb2 inactivation in SCs during nerve repair inhibits SC redifferentiation and thus remyelination, supporting the crucial role of Zeb2 in myelin regeneration in the PNS. However, we did not detect any difference in Sox2 or Hey2 mRNA expression in the mutant injured nerves 7 d post-transection, at which time regenerating mouse nerves would have reached the midpoint of axonal regrowth, as compared to the control injured sciatic nerves (Supplementary Fig. 8) . Thus, we cannot rule out the possibility that Zeb2 may utilize other mechanisms after injury for SC regeneration and remyelination.
Deficient radial axonal sorting and myelination caused by Zeb2 loss could severely disrupt nerve conduction and, consequently, motor function in Zeb2 mutant mice, paralleling motor disabilities and delayed walking in humans with MOWS. The phenotypic variation between humans with haplo-insufficient mutations could be attributed to a differential sensitivity to gene dosage across species or dominant-negative effects of human mutant proteins. Strikingly, we find that the ZEB2 R22G detected in a MOWS patient failed to associate with HDAC1/2-NuRD and blocked SC differentiation, suggesting that developmental defects caused by ZEB2 mutations affecting a functional domain may contribute to neuropathies and motor dysfunction seen in these patients. Given that ZEB2-mediated functions are vital for SC development and myelination, it may serve as a pivotal hub of the myelination regulatory network. Augmenting HDAC1/2-NuRD-dependent ZEB2 activity and inhibiting Notch signaling could potentially provide a novel therapeutic means of reversing adverse neuropathies seen in people with MOWS.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Animals. Zeb2 loxP/loxP mice 21 were crossed with Dhh-cre 17 mice to obtain Zeb2 loxP/+ ;Dhh-cre +/− mice, which were then bred with Zeb2 loxP/loxP mice to produce control (Zeb2 loxP/+ ;Dhh-cre +/− ) and Zeb2 cKO offspring (Zeb2 loxP/loxP ; Dhh-cre +/− ). Littermates Zeb2 loxP/loxP or Zeb2 loxP/+ ;Dhh-cre +/− mice were used as controls. Transgenic Notch reporter (TNR) mice were obtained from the Jackson Laboratory (Stock 018322) and bred with Zeb2 loxP/+ ;Dhh-cre +/− mice to generate Zeb2 loxP/loxP ; Dhh-cre +/− ;Notch-GFP mice. Recombination, perinatally or after sciatic nerve transection, was achieved by crossing Zeb2 loxP/loxP mice with the inducible Cre recombinase Cre-ERT2 under the control of the Plp1 promoter (Plp1-cre ERT ) followed by tamoxifen injection 23 . Zeb2 loxP/loxP ;Plp1-cre ERT mice were then bred to mice containing a Cre-responsive Rosa26 loxP-flanked stop tdTomato reporter allele. Animals of either sex were used in the study and littermates were used as controls unless otherwise indicated. The mouse strains used in this study were generated and maintained on a mixed C57Bl/6;129Sv background and housed in a vivarium with a 12-h light/dark cycle. No more than 4 adult mice were housed in the same cage per IACUC regulations at CCHMC. All animal experiments were conducted in mice of both genders. All animal use and studies were approved by the Institutional Animal Care and Use Committee at Cincinnati Children's Hospital, USA.
Isolation, growth and differentiation of primary rat Scs. Rat SCs from sciatic nerves of newborn rats (1-2 d old) were isolated as described previously 51 . SCs were grown routinely in DMEM/10% FBS (Life Technologies), supplemented with 10 ng/ml Neuregulin 1 (Nrg1; R&D Systems) and 5 µM forskolin (Sigma) plus l-glutamine and penicillin/streptomycin, hereafter termed SC proliferation medium. Cells between passages 2 and 6 were used in all experiments. >95% SC purity was achieved, assessed by Sox10 and S100β staining. To initiate differentiation, SCs were washed 4 times with DMEM and then cultured in differentiation medium containing DMEM/0.5% FBS and 1 mM dibutyryl cyclic AMP (Sigma) with l-glutamine and penicillin/streptomycin, for the length of time indicated in the text, depending on the assays used. All tissue culture containers and coverslips were coated with 50 µg/ml poly-L-lysine (Sigma) in PBS for at least 30 min at room temperature and then rinsed in distilled water. Purified rat SCs seeded on coverslips were fixed in 4% paraformaldehyde (PFA) for 20 min and washed in 1× PBS 4 times before immunofluorescence staining.
Immunostaining, In situ hybridization and electron microscopy. The sciatic nerves of mice at defined ages were dissected and fixed for 45 min in 4% PFA, embedded in OCT, cryoprotected in 25% sucrose and sectioned at 9 µm as longitudinal sections. For BrdU pulse labeling, animals at P1 were injected subcutaneously with 100 mg BrdU/kg body weight 2 h before sciatic nerve collection. For immunostaining, we used antibodies to Zeb2 (Santa Cruz Biotechnology, sc-48789), Sox10 (goat, Santa Cruz Biotechnology, sc-17342; rabbit, Millipore; AB5727), Oct6 (goat; Santa Cruz Biotechnology, sc-11661), Krox20 (rabbit; Covance, PRB-236P), MBP (goat; Santa Cruz Biotechnology, sc-13914), Sox2 (goat; Santa Cruz Biotechnology, sc-17320), c-Jun (rabbit; Epitomics, 1254-1), Hey2 (rabbit; Proteintech, 10597-1-AP); Ki67 (rabbit; Thermo Scientific, RM-9106), BrdU (rat; Abcam, ab6326), cleaved caspase 3 (rabbit; Cell Signaling, #9661), S100β (mouse; Sigma, SAB1402349); GFP (rabbit; Life Technologies, A11122); c-MYC (mouse; Santa Cruz Biotechnology, sc-40), Flag (mouse; Cell Signaling, #8146) and HA-tag (Upstate, 50-171-890). Secondary antibodies conjugated to Cy2, Cy3 or Cy5 were from Jackson ImmunoResearch Laboratories catalog numbers 705-165-147, 705-225-147, 711-225-152, 711-165-152, 711-175-152, 715-165-150 and 712-165-150. All images were acquired using a Zeiss LSM 510 or Nikon C2 + confocal microscope. RNA in situ hybridization was performed using digoxigenin-labeled riboprobes as described previously 52 . The probes used were murine Mbp and Mpz. Detailed protocols are available upon request. For electron microscopy, mice were perfused with 4% PFA, 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.2. Sciatic nerves were dissected and fixed in the same fixative solution overnight. Nerves were rinsed in PBS, postfixed in 1% OsO4 in PBS for 1 h, dehydrated in graded ethanol, infiltrated with propylene oxide and embedded in Epon. Semi-thin sections were stained with toluidine blue, and thin sections were stained with lead citrate. transient transfections and luciferase assays. For plasmid transfections, rat SCs were transfected with expression vectors using Lipofectamine 3000 (Life Technologies) per the manufacturer's protocol and assayed for immunocytochemistry or qPCR analysis. pHA-Sox2 was purchased from Addgene.
For siRNA knockdown in SCs, we used Lipofectamine RNAiMAX (Life Technologies) per the manufacturer's instructions. SCs were induced to differentiate after 48 h of transfection for 24 h before harvesting for immunocytochemistry or qPCR analysis. For sequential siRNA knockdown, SCs in proliferation medium was transfected with Zeb2-specific siRNA for 24 h before Sox2 or Hey2 siRNA transfection. Triple knockdown was performed in the order of Zeb2, Hey2 and Sox2 siRNA, each separated by a 24-h interval. For DAPT (Sigma) treatment, 48 h after transfection with scramble or Zeb2 siRNA, SCs on coverslips or in 12-well culture dishes were induced to differentiate with 1 mM dbcAMP and treated with DMSO or 5 µM DAPT for 4 d and then assayed for immunocytochemistry or qRT-PCR analysis. Proliferation was assessed by immunostaining for Ki67 in Sox10 + SCs seeded on PLL-coated coverslips for 2 d. Differentiation was assessed by immunostaining for Oct6 or Krox20. Multiple images were taken from each coverslip to obtain representative images from all areas of the coverslip, and at least 400 cells/coverslip were counted using ImageJ (NIH). For quantitation, GFP + or fusion tag-expressing cells were counted, and the percentage of GFP + /fusiontag + cells that expressed the protein of interest was determined. At least 100 GFP + or fusion-tag + cells/coverslip were counted.
For reporter assays, purified rat SCs were transfected with pGL3luciferase reporters containing inserts from 2 kb upstream of Sox2 TSS or 3.9 kb upstream of Hey2 TSS and with expression vectors using Lipofectamine 3000 (Life Technologies) per the manufacturer's protocol, and were assayed 48 h posttransfection for luciferase activity using a Promega luciferase assay kit according to the manufacturer's instructions. The pSV-β-galactosidase control vector was included to control for variable transfection efficiencies between independent experiments (n ≥ 3). Mutant Sox2 promoter luciferase reporter was generated by mutating a Zeb2 consensus binding site (P1; −1.1 kb from TSS; Fig. 5i) into an EcoRI site, and mutant Hey2 promoter luciferase reporter was generated by mutating a Zeb2 binding site into an EcoRI site.
western blotting and coimmunoprecipitation. For western blotting, the perineurium and epineurium were removed from sciatic nerves before snap-freezing and storage at −80 °C. Sciatic nerves and rat SCs were lysed in RIPA buffer, containing protease and phosphatase inhibitors. Western blot analysis was performed as described previously 38 . GAPDH was used as an input control. For immunoprecipitation, HEK 293T cells cultured in 10% FBS/DMEM were transfected with expression vectors using PolyJet (Signagen) for 48 h. Cells were lysed in NP-40 buffer (170 mM NaCl, 10 mM EDTA, 50 mM Tris pH 7.4, 50 mM NaF and 0.5% NP-40) supplemented with protease inhibitor cocktail and phosphatase inhibitors (Roche Diagnostics Inc.). A total of 300 µg of cell lysate proteins were incubated with 2 µg IgG or appropriate antibodies and immunoprecipitated using Protein A/G beads (Santa Cruz Biotechnology, sc-2003). Western blotting was performed using chemiluminescence with the ECL kit (Pierce). The antibodies used were anti-Zeb2 (Millipore, ABT-332), anti-Flag (rabbit #14793 or mouse #8146, Cell Signaling), anti-Myc (Santa Cruz, sc-40). For coimmunoprecipitation of endogenous NuRD subunits, extracts of HEK 293T cells transiently expressing Flag-tagged ZEB2 WT or Flag-tagged ZEB2 R22G were precipitated in a Flag-dependent manner and eluted using 3XFlag peptides according to Verstappen et al 10 . Co-immunoprecipitation experiments showing endogenous interaction between Zeb2 and HDAC1/2 were performed by incubating protein lysates from purified rat SCs with anti-Zeb2 antibody followed by immunoprecipitation using Protein A/G beads and detection of HDAC1/2 using HDAC1/2-specific antibodies. Antibodies used were HDAC1 (Santa Cruz, sc-7872), HDAC2 (Abcam #7029), Mi2 (Santa Cruz, sc-11378), MTA-1 (Santa Cruz, sc-9446), MTA-2 (Santa Cruz, sc-28731), RbAp48 (Abcam, 38185) and CtBP (Sigma, C8741). Secondary antibodies conjugated to HRP were from Jackson ImmunoResearch Laboratories. catalog numbers 111-035-144 and 111-035-003.
npg RnA-seq and data analysis. RNA from P7 control and Zeb2 cKO sciatic nerves were extracted using TRIZOL (Life Technologies) followed by purification using an RNeasy Mini Kit (Qiagen). RNA-seq libraries were prepared using Illumina RNA-Seq Preparation Kit and sequenced by HiSeq 2000 sequencer. RNA-seq reads were mapped using TopHat with default settings (http://ccb.jhu. edu/software/tophat/index.shtml). TopHat output data were then analyzed by Cufflinks to (1) calculate FPKM values for known transcripts in mouse genome reference and (2) test the changes of gene expression between Zeb2 cKO and control. Gene ontology (GO) analysis was performed using The Database for Annotation, Visualization and Integrated Discovery (DAVID; http://david.abcc. ncifcrf.gov). The heat map was generated based on log 2 [FPKM] by AltAnalyze 53, 54 with normalization of rows relative to row mean. chIP assays. ChIP assays were performed as described with minor modifications 38, 55 . Briefly, purified rat SCs grown in proliferation and differentiation (9 h in 1 mM cAMP-containing medium conditions; ~20 million cells) were fixed for 10 min at room temperature with 1% formaldehyde-containing medium. Nuclei were pelleted and sonicated in sonication buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA and protease inhibitor cocktail). Sonicated chromatin (~300 µg) was used for immunoprecipitation by incubation with IgG or rabbit anti-Zeb2 antibody (H-260; Santa Cruz Biotechnology sc-48789; 4 µg) overnight at 4 °C. We kept 10% of the chromatin used for each ChIP reaction as input DNA. Pre-rinsed protein A/G plus agarose beads (50 µl) were added to each ChIP reaction and incubated for 1 h at 4 °C. The beads were then incubated in 200 µl elution buffer at 65 °C for 20 min to elute immunoprecipitated materials. For ChIP, SCs at 70-90% confluency were transfected with control or Zeb2 siRNA for 48 h using Lipofectamine RNAiMAX per the manufacturer's instructions and induced to differentiate for 9 h with 1 mM cAMP. ChIP was performed using anti-HDAC1 (Active Motif #40967) and HDAC2 antibody (Abcam #7029). Real-time PCR was performed using quantitative SYBR green PCR mix (Bio-Rad). The relative fold-enrichments were determined by 2 −∆CT methods as described 38 . Samples were normalized to input chromatin. Primers used for ChIP-qPCR analysis:
Sox2 proximal promoter (P1): forward ATTGGTGGAGGAGGGAGTTA; reverse TATGGCTGACTGTAGAGCTAGG;
Sox2 proximal promoter (P2): forward CTGCACCTGCACCTCTG; reverse CAGCGTTCCCAGGATGG;
Sox2 proximal promoter (P3): forward CTCCACCCGTGTTTCCTAAAT; reverse CTTCTGCCCTCTAAGTCACAAA;
Hey2 proximal promoter (-3.9 kb from TSS): forward: GCTCACAATA GCCTGTAGTT; reverse: AAGTCAGTCTCTGTCCTGGT.
Oct6 proximal promoter (-0.8 kb from TSS): forward: TCCTAGAGCTCG CATCTCC; reverse: ATCGGCTTGGGCTTCAC.
Oct6 proximal promoter (-3.9 kb from TSS): forward: GTGTCCGT ATGTCTTCGAGATG; reverse: ACACGGTGCTATTCACACAA.
Jun proximal promoter (-6 kb from TSS): forward: CCCAAGAC CTGTGTGAGAAT; reverse: CTCACAGTTTGATTGGCTGAAA.
Distal control region ChIP-PCR: Sox2 (+25 kb TSS): forward GAACAGATG AGTGTTGCCTTTAG; reverse ACTCCCTGGACCAAACATAC;
Hey2 (+20 kb TSS): forward GGAAACTGTATACGGCCTCTG; reverse GATCTGCATCGCCCTTTCT;
Oct6 (+18 kb TSS): forward GTAGAGGAAAGCAGAGGAAAGG; reverse GAATCCCATAGCCAGACATGAT.
RnA isolation and quantitative real-time PcR. RNA from purified rat SCs or control and Zeb2 cKO mouse sciatic nerves was extracted using TRIZOL (Life Technologies). cDNA was synthesized from 1 µg RNA using iScript Reverse Transcription Supermix (BioRad) according to the manufacturer's instructions. qPCR was performed using quantitative SYBR green PCR mix (BioRad) as previously described 56 . PCR primer sequences are available upon request.
RnA-seq and data analysis. RNA-seq libraries were prepared using Illumina RNA-Seq Preparation Kit and sequenced by a HiSeq 2000 sequencer. All RNA-Seq data were aligned to mm9 using TopHat 57 with default settings. We used Cuff-diff 58 to (1) estimate FPKM values for known transcripts and (2) analyze differentially expressed transcripts. In all differential expression tests, a difference was considered significant if the q value was less than 0.05 (Cuff-diff default).
Heat map of gene expression was generated using R language (http://www.rproject.org). GO-analysis of gene expression changes was performed using Gene Set Enrichment (GSEA, http://www.broadinstitute.org/gsea/index.jsp). We used ToppCluster (https://toppcluster.cchmc.org/) to construct the network of genes belonging to over-represented GO-term categories. tamoxifen injections. We used Tamoxifen (Sigma) dissolved to a stock concentration of 20 mg/ml in a vehicle of ethanol and sunflower seed oil (1:9 v/v). For perinatal tamoxifen injections, tamoxifen stock was injected i.p. at 2 mg/100 µl for 5 consecutive d to lactating mothers, thus administering tamoxifen to pups, beginning at P0. Sciatic nerves of pups were analyzed on P14 for electron microscopy. For adult tamoxifen treatment, 100 µl (2 mg/100 µl) was administered by i.p. injection once daily for 5 consecutive d to 4-6 week-old mice. Mice were treated again for 5 d after a 2-d rest period. Control mice were treated identically.
In vivo drug treatment. Control and Zeb2 cKO were injected on P2, P3, P5 and P7 with the Notch signaling (γ-secretase) inhibitor LY411575 (Selleckchem) at 0.30 mg kg −1 per day. Sciatic nerves were fixed in 4% PFA on P8 for immunostaining. LY411575 was diluted in a mixture of corn oil and EtOH (95:5 v/v). Vehicle was corn oil and EtOH (95:5 v/v). generation and transduction of lentivirus. Lentivirus was produced by transfection of DN-MAML lentivirus construct (MAML1 1-305 subcloned into BamHI and XhoI sites of PLU-ires-GFP mod vector, a kind gift from A.J. Capobianco) into HEK 293T cells with the packaging vectors psPAX2 and pMD2.G using Polyjet in vitro DNA transfection reagent (Sigmagen) according to the instructions of the manufacturer. The supernatant was collected 72 h after transfection and frozen in liquid nitrogen. A titer of 10 7 /µl was achieved. SCs previously transfected with control or Zeb2 siRNA for 24 h were infected with control GFP lentivirus or DNMAML-GFP lentivirus in the presence of 4 µg/ml Polybrene for 48 h before harvesting for RNA.
ZeB2 variant identification. The novel ZEB2 variant c. 64A>G [p.(Arg22Gly)] was identified by targeted diagnostic sequencing of the coding exons of ZEB2 in a patient with a facial gestalt reminiscent of MOWS (OMIM 235730). The patient had mild manifestation of MOWS phenotype. This mutation was not detected in any other patients and is not contained in the ExAC database. This variant is atypical since missense mutations in ZEB2 are very rare in MOWS; usually truncating mutations are found. Due to the young age (4 years old) of the patient, peripheral nerve-related phenotyping was clinically impossible to test for, and therefore we could not assess the peripheral nerve related phenotype.
Sciatic nerve transection surgeries. Sciatic nerve transection was performed 10 d after the last tamoxifen injection in 6-8 week-old mice. Under general anesthesia after injection of a mixture of ketamine (90 mg/kg) and xylazine (10 mg/kg), right sciatic nerves were exposed and transected at the midthigh level. Exposed left sciatic nerves were used as uncut controls. Mice were treated with tamoxifen for an additional 8 d following injury. Nerves were collected 14 d after surgery and processed for immunohistochemistry. compound muscle action potential recording. To analyze nerve conduction and motor unit function, single CMAPs were recorded in vivo from the lateral gastrocnemius muscles of wild-type littermate controls or Zeb2 cKO mice during electrical stimulation of the sciatic nerve under sodium pentobarbital anesthesia (50 mg/kg, i.p.). The lateral gastrocnemius muscle was first exposed from the knee to approximately 6 mm above the ankle. A small opening was then made in the overlying fascia to facilitate implantation of the recording wires into the muscles. Next, the sciatic nerve was exposed near the biceps femoris muscles. Polymidecoated steel recording wires (California Fine Wire Inc. stainless steel 304: size = 0.0092 and insulated with polyimide; material #100192) were then implanted into the lateral gastrocnemius muscles and reference wires were inserted under the nearby skin. To induce electrical activation of the nerve in vivo, a concentric bipolar stimulating electrode was placed on the sciatic nerve. CMAPs were amplified and obtained using a Micro 1401 data acquisition unit and analyzed using Spike2 software (Cambridge Electronic Design, Cambridge, UK). Three successive electrical stimulations of the sciatic nerve at 2 mA (0.25-0.5 Hz, 0.1 ms duration) were initiated immediately proximal to the tibial, sural and common peroneal branches via a stimulus isolator (WPI Inc.) connected to the Micro 1401. After recording, the sciatic nerve was axotomized distal to the site of concentric electrode placement and the proximal end of the sciatic nerve was stimulated to ensure CMAPs were generated from direct nerve stimulation. Conduction velocity was calculated after determining the latency of CMAP onset relative to the stimulus artifact induced by electrical stimulation of the sciatic nerve and the distance between recording and stimulating electrodes measured directly on the nerve. Peak CMAP amplitude and CMAP duration were calculated from each stimulation paradigm. The average of the stimulations of the sciatic nerve for each paradigm were obtained and then averaged across animals.
Heat hypersensitivity assessments. Mice at 3-4 weeks old were acclimatized individually in a box of at least 15 × 12 × 10 cm 3 in dimensions for 15 min. Mice were then gently held and both hindpaws were immersed into a 50 °C hot water bath. Latency (in s) to withdrawal from the heat stimulus was determined. Three trials were performed with a 5-min interval in between each trial. The average of these three trials was then determined to obtain the baseline withdrawal latency. Next, mice were anesthetized under 3% isoflurane in order to induce cutaneous inflammation. Using a syringe with a 30 G needle, approximately 10 µL of 3% carrageenan (in 0.9% NaCl) was injected into the right hairy hindpaw skin. 24 h later, thermal withdrawal latency using the methods described above were measured again to determine heat hypersensitivity (withdrawal latency) post inflammation 59, 60 . morphometric analysis. The morphometric measurements in the early postnatal Zeb2 iKO experiment and the axon regeneration/remyelination assays were performed in Toluidine blue-stained semi-thin sections (0.5 µm). An entire sciatic nerve cross section per animal was reconstructed by merging several high magnification photographs taken by bright field microscopy at 100× magnification. The quantifications of the 1:1 promyelinating cells, myelinated fibers and numbers of axon were performed by manually counting all of the figures present in the entire sciatic nerves cross section using the cell counter plugin from ImageJ software (National Institutes of Health).
The number of myelinated axons per nerve, the G-ratio and the number of unmyelinated axons in Remak bundles were analyzed in ultrathin sections using a JEOL 1200 EXII or Hitachi H7650 electron microscope. Quantification was done by manually counting myelinated or unmyelinated axons present in the sciatic nerves using the cell counter plugin from ImageJ software. For G-ratio analysis, images were calibrated based on the scale bar corresponding to the magnification used for each micrograph. The axons (without myelin) and fiber areas (including myelin) of randomly chosen fibers were measured, except for those surrounded by a Schmidt Lanterman incisure. The axon and fiber diameters were estimated as 2 area p and the G-ratio was calculated as axon diameter/fiber diameter. At least 100 nerve fibers per animal (n = 3 for each group) were analyzed.
For quantification of labeled cells in transfection studies, since the ZEB2, ZEB 2R22G and ZEB ∆CtBP expression plasmids carry a GFP-reporter, GFP + cells represent ZEB2 or ZEB2-mutant transfected cells. The quantification was performed by manually counting antibody co-labeled cells based on the total number of transfected cells indicated by GFP expression.
Statistical analysis. All analyses were done using Microsoft Excel or GraphPad Prism 6.00 (San Diego California, http://www.graphpad.com). Data are shown in dot plots as mean ± s.e.m. or as box-and-whisker plots; P < 0.05 is deemed statistically significant. Data distribution was assumed to be normal, but this was not formally tested. Count data was assumed to be non-parametric, and appropriate statistical tests were used. Statistical analysis was performed by two-tailed unpaired Student's t tests, Mann-Whitney test, one-way ANOVA with post-hoc analysis by Tukey's multiple comparison test, two-way repeated measures ANOVA with Sidak's multiple comparisons test, or as indicated. Quantifications were performed from at least three experimental groups in a blinded fashion. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those generally employed in the field. No randomization was used to collect all the data; they were quantified blindly. No animals or data points were excluded from analyses.
A Supplementary methods checklist is available.
data availability. All the RNA-seq data have been deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE74381. The data that support the findings of this study are available from the corresponding author upon reasonable request.
